Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs

Gastroenterology Clinics of North America

Volumn 38, Issue 2, 2009, Pages 305-314

  Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anti inflammatory therapy; Aspirin; Gastrointestinal bleeding; Myocardial infarction; Peptic ulcer disease; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; IBUPROFEN; LANSOPRAZOLE; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; VALDECOXIB;

AGE; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DRUG FATALITY; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HEART DEATH; HEART INFARCTION; HEARTBURN; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; OSTEOARTHRITIS; POLYP; RECURRENT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; STOMACH PROTECTION; STOMACH ULCER; STROKE; THROMBOEMBOLISM;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; PAIN; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 65549164331     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.03.006     Document Type: Review

References (40)

1. Sukel M.P., van der Linden M.W., Chen C., et al. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf 17 (2008) 9-19
2. Scheiman J.M., and Fendrick A.M.F. Summing the risks of NSAID therapy. Lancet 369 (2007) 1580-1581
3. McGettigan P., Han P., Jones L., et al. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol 65 (2008) 927-934
4. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure: a meta-analysis. Ann Intern Med 121 (1994) 289-300
5. Warner T.D., and Mitchell J.A. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371 (2008) 270-273
6. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
7. Brune K., Hochberg M., Schiff M., et al. The platelet inhibitory effects of the combination of naproxen sodium or acetaminophen with low-dose aspirin. [abstract]. Arthritis Rheum 56 Suppl (2007) S359
8. Gladding P., Webster M., Farrell H., et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101 (2008) 1060-1063
9. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
10. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 11 (2005) 1092-1102
11. Aldington S., Shirtcliffe P., Weatherall M., et al. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J 18 (2005) U1755
12. Aldington S., Shirtcliffe P., Weatherall M., et al. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 118 (2005) U1684
13. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 11 (2005) 1071-1080
14. Arber N., Eagle C.J., Spicak J., et al. PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 9 (2006) 885-895
15. PRECISION: Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen Or Naproxen. ClinicalTrials.gov Identifier: NCT00346216.
16. Solomon S., Wittes J., Finn P., et al. Cardiovascular risk of celecoxib in 6 Randomized Placebo-Controlled Trials. The cross trial safety analysis. Circulation 117 (2008) 2104-2113
17. Solomon D., Glynn R., Rothman K., et al. Subgroup analyses to determine cardiovascular risk associated with non-steroidal anti-inflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59 (2008) 1097-1104
18. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 296 (2006) 1633-1644
19. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
20. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 (2006) e33. http://dx.doi.org/10.1371/journal.pctr.0010033 Available at:
21. Fries S., Grosser T., Price T.S., et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (2006) 55-64
22. Scheiman J.M. NSAIDs, cytoprotection, and gastrointestinal injury. Gastroenterol Clin North Am 25 (1996) 279-298
23. Wallace J.L., McKnight W., Reuter B.K., et al. NSAIDs-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
24. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
25. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
26. Jones R., Rubin G., Berenbaum F., et al. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 121 (2008) 464-474
27. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 4 (2002) CD002296
28. Hooper L., Brown T.J., Elliott R., et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: a systematic review. BMJ 329 (2004) 948
29. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long term users of non-steroidal anti-inflammatory drugs: results of a double-blind randomized, multicenter, active and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med 162 (2002) 169-175
30. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX 2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
31. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
32. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared to lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
33. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
34. Ray W.A., Chung C.P., Stein C.M., et al. Risk of peptic ulcer hospitalizations in users of NSAIDS within gastroprotective cotherapy versus coxibs. Gastroenterology 133 (2007) 790-798
35. Chan F.K.L., Wong V.W.S., Suen B.Y., et al. Combination of a cyclooxygenase-2 inhibitor and a proton pump inhibitor for the prevention of recurrent ulcer bleeding in patients with very high gastrointestinal risk: a double-blind, randomized trial. Lancet 369 (2007) 1621-1626
36. Zhang W., Moskowitz R.W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI Evidence-based, Expert Consensus Guidelines. Osteoarthritis Cartilage 16 (2008) 137-162
37. Chan F.K.L., Abraham N., Scheiman J.M., et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-Inflammatory Drugs and Anti-Platelet Agents. Am J Gastroenterol 103 (2008) 2908-2918
38. van Staa T.P., Smeeth L., Persson I., et al. What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol 37 (2008) 405-413
39. Fendrick A.M., Bandekar R.R., Chernew M.E., et al. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum 47 (2002) 36-43
40. Bhatt D., Scheiman J.M., Abraham N., et al. ACCF/ACG/AHA clinical expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 118 (2008) 1894-1909